Duopharma Biotech BhdXKLS:7148 83 EBITDA Margin % is 23.00% as of Mar. 2026, which is 23% above its 10-year median of 18.63. GuruFocus rates XKLS:7148 with a GF Score™ of 83/100 and a GF Value™ of RM1.52 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 955 Drug Manufacturers companies, Duopharma Biotech Bhd ranks better than 69.63% on this metric.
Duopharma Biotech Bhd (XKLS:7148) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Duopharma Biotech Bhd EBITDA Margin % Related Terms
Duopharma Biotech Bhd EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Duopharma Biotech Bhd's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:7148 vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Duopharma Biotech Bhd's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Duopharma Biotech Bhd EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Duopharma Biotech Bhd's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Duopharma Biotech Bhd's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Duopharma Biotech Bhd (XKLS:7148) has a EBITDA Margin % of 23.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Duopharma Biotech Bhd and its competitors. This is 23% above median its historical median of 18.63. Over the past decade, Duopharma Biotech Bhd's EBITDA Margin % has ranged from 17.28 to 20.83. According to the industry distribution chart, Duopharma Biotech Bhd ranks #290 out of 955 companies in the Drug Manufacturers industry, placing it in the top 30.4%.
Is Duopharma Biotech Bhd's EBITDA Margin % too high?
Duopharma Biotech Bhd's current EBITDA Margin % of 23.00% is 23% above median its 10-year median of 18.63. Over the past 10 years, this metric has ranged from a low of 17.28 to a high of 20.83. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Duopharma Biotech Bhd's value of 23.00% is 84.9% above this industry median. Based on the distribution chart, Duopharma Biotech Bhd ranks #290 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Duopharma Biotech Bhd has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Duopharma Biotech Bhd's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Duopharma Biotech Bhd ranks #290 out of 955 companies for EBITDA Margin %. This puts Duopharma Biotech Bhd in the upper half of its industry. The industry median EBITDA Margin % is 12.44. Duopharma Biotech Bhd's value of 23.00% is 84.9% above this benchmark. Historically, Duopharma Biotech Bhd's own EBITDA Margin % has ranged from 17.28 to 20.83 over the past decade. While the company's 10-year median is 18.63 vs. the industry median of 12.44, Duopharma Biotech Bhd has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Duopharma Biotech Bhd's current EBITDA Margin % of 23.00% is 84.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Duopharma Biotech Bhd and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Duopharma Biotech Bhd's current EBITDA Margin % is 23.00%, which is 23% above median its own 10-year median of 18.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duopharma Biotech Bhd stock overvalued right now?
Based on GuruFocus' analysis, Duopharma Biotech Bhd (XKLS:7148) is currently considered Modestly Undervalued. The stock's GF Value™ is RM1.52, compared to a current price of RM1.20 — trading 21.1% below its estimated fair value. The current EBITDA Margin % is 23.00%, which is 23% above median its 10-year median of 18.63 and 84.9% above the Drug Manufacturers industry median of 12.44. Duopharma Biotech Bhd's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Duopharma Biotech Bhd (XKLS:7148), the current EBITDA Margin % is 23.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Duopharma Biotech Bhd (XKLS:7148) Overvalued in 2026?
Based on GuruFocus' analysis, Duopharma Biotech Bhd stock appears to be undervalued.
The current stock price of RM1.20 is trading 21.1% below its estimated GF Value™ of RM1.52.
GuruFocus considers Duopharma Biotech Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:7148:
EBITDA Margin %: 23.00% (23% above median its 10-year median of 18.63)
GF Value™: RM1.52 vs. price of RM1.20 (21.1% below fair value)
Industry Position: 84.9% above the Drug Manufacturers median (#290 of 955)
No single metric tells the full story. See the XKLS:7148 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. The company develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer, and exporter of pharmaceutical products and medicines. Geographically, the company generates the majority of its revenue from Malaysia.
83GF Score
Get the complete analysis for XKLS:7148
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7148 has been successfully added to your 
